Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 4/20 | 0.31 |
| ▸ | HTR2B | P41595 | 4/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629949 | 0.84 | TAAR1 (0.38) | ALDH1A1TSHRTRPA1TAAR1IDO1 | |
| SCHEMBL29466647 | 0.84 | TAAR1 (0.38) | ALDH1A1TSHRTRPA1TAAR1IDO1 | |
| SCHEMBL6217138 | 0.82 | ALDH1A1 (0.50) | ALDH1A1TSHRTRPA1TAAR1GABRA1 | |
| SCHEMBL4243083 | 0.82 | EED (0.41) | ALDH1A1TSHRTAAR1 | |
| SCHEMBL29386736 | 0.82 | EED (0.41) | ALDH1A1TSHRTAAR1 | |
| SCHEMBL695878 | 0.82 | TAAR1 (0.43) | ALDH1A1TSHRTAAR1 | |
| SCHEMBL12971446 | 0.82 | AHR (0.31) | AHR | |
| SCHEMBL29649325 | 0.82 | TAAR1 (0.43) | ALDH1A1TSHRTAAR1 | |
| SCHEMBL14253791 | 0.82 | CYP3A4 (0.36) | ALDH1A1TSHRTAAR1IDO1HTR2C | |
| SCHEMBL12391372 | 0.80 | TRPA1 (0.33) | ALDH1A1TSHRTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010880-A | Organic compound and organic electroluminescent device comprising same | 西安交通大学 | 2026-05-12 | — | — | CN | disclosed |
| EP-3843728-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119431362-A | Substituted heteroaryl carboxylic acid compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2025-02-14 | — | — | CN | disclosed |
| CN-119368027-A | Composite nanofiltration membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-115243764-B | Heterocyclic derivatives as TRMP antagonists | 奇华顿股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-117820333-A | KRAS G12C inhibitors | 伊莱利利公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117222628-A | Compound for inhibiting apoptosis and preparation method thereof | 中国科学院上海有机化学研究所 | 2023-12-12 | — | — | CN | disclosed |
| CN-114828964-B | KRAS G12C inhibitors | 伊莱利利公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | ELI LILLY AND COMPANY | 2023-10-26 | — | — | US | disclosed |
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | ELI LILLY AND COMPANY | 2023-10-26 | — | — | US | disclosed |
| EP-1891006-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | Wyeth a Corporation of the State of Delaware (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20070004719-A1 | Inhibitors of cytosolic phospholipase A2 | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006128142-A2 | INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 | WYETH (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| WO-2000006557-A1 | NOVEL PROCESS FOR MAKING IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | ALDH1A1 3567/4885TSHR 1495/4885TRPA1 317/4885 |
| US-20230339968-A1 | KRAS Gl2C INHIBITORS | KRAS, NRAS, GLS2 | ALDH1A1 1144/4885TSHR 2384/4885TRPA1 3706/4885 |
| US-20070265304-A1 | 1,2,3,4-TETRAHYDRO-QUINOLINE DERIVATIVES AS CETP INHIBITORS | CETP, NPC1, CES1 | ALDH1A1 3257/4885TSHR 4605/4885TRPA1 4234/4885 |
| US-20070004719-A1 | Inhibitors of cytosolic phospholipase A2 | PLA2G4B, PLA2G4A, PLA2G12A | ALDH1A1 2405/4885TSHR 4125/4885TRPA1 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.